Physician profile
Brian Horn
NPI 1518922574
$3,010.18
in general payments reported to CMS, 2019-2025
29 companies · $782 in 2025
The $782 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $184 · 2022: $69.21 · 2023: $629 · 2024: $770 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,181.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $422.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $419.37 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $349.66 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $292.72 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Pfizer INC. | $222.88 | 2019-2025 | |
| Dexcom, INC. | $184.66 | 2022-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $149.64 | 2019-2025 | |
| Astellas Pharma US INC | $125.05 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $89.92 | 2019-2025 | Trelegy Ellipta, Pediarix, Penmenvy |
| Abbott Laboratories | $83.44 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Shield Therapeutics INC | $80.62 | 2023-2024 | Accrufer |
| Exact Sciences Corporation | $79.31 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $56.62 | 2023 | Qelbree |
| Idorsia Pharmaceuticals US INC | $50.29 | 2023-2024 | Quviviq |
| Scilex Pharmaceuticals INC. | $43.61 | 2023-2025 | Ztlido |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $43.34 | 2019-2020 | |
| Amgen INC. | $41.91 | 2025 | Evenity |
| Shire North American Group INC | $37.98 | 2019 | |
| Averitas Pharma INC. | $33.77 | 2024 | Qutenza |
| Ironshore Pharmaceuticals INC. | $33.42 | 2019 | |
| Phathom Pharmaceuticals, INC. | $26.91 | 2025 | Voquezna |
| Lundbeck LLC | $24.22 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.36 | 2019 | |
| Medtronic USA, INC. | $18.49 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.28 | 2025 | Xifaxan |
| Seqirus USA INC | $17.11 | 2020 | |
| Genentech USA, INC. | $15.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.05 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.